Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Lorenzo Antonuzzo

University of Florence

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Articles (21)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Collaborators (15)

Fabian Finkelmeier

University Hospital Frankfurt

GERMANY

View details

David J. Pinato

Imperial College London

UNITED KINGDOM

View details

Hong Jae Chon

Associate Professor

CHA Bundang Medical Center

SOUTH KOREA

View details

Salvatore Corallo

Researcher

University of Pavia

ITALY

View details

Oscar Juan-Vidal

SPAIN

View details

Barletta Giulia

Ricercatore sanitario; MD

Ospedale Policlinico San Martino

ITALY

View details

ilhwan kim

Associate Professor

Inje University Ilsan Paik Hospital

SOUTH KOREA

View details

Jin Won Kim

Professor

Seoul National University Hospital

SOUTH KOREA

View details

Michele Ghidini

Docenti di ruolo di IIa fascia

University of Insubria

ITALY

View details

Claudiu T Supuran

University of Florence

ITALY

View details

Giovanni Farinea

University of Turin

ITALY

View details

Andrea Casadei-Gardini

Ospedale San Raffaele

ITALY

View details

Lorenza Rimassa

Head of Hepatopancreatobiliary Oncology Unit

Humanitas University

ITALY

View details

Vanesa GREGORC

Candiolo Cancer Institute

ITALY

View details

Jun Zhang

Associate Professor

University of Kansas Medical Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Lorenzo Antonuzzo

Research Interests

Explore related searches

Articles (21)

Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-Immunotherapy

APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer

Bone metastases from neuroendocrine neoplasms: Results of an Italian nationwide survey of natural history and management

Braf-mutant metastatic non–small-cell lung cancer: Real world data from the Italian biomarker atlas database

Design and Synthesis of Bendamustine-Carbonic Anhydrase Inhibitors with Antiproliferative Effects in Clear Cell Renal Cell Carcinoma

Development and Psychometric Validation of the Self‐Care of Cancer Inventory (SC‐CI)

Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: Results from the MAVERIC Phase II Trial (1499 WORDS MAIN TEXT)

Navigating Disappearing Liver Metastases in Colorectal Cancer: A Review of Surgical and Non-Surgical Approaches

Radiomics on 177Lu-DOTATATE Posttreatment Scans: Feasibility, Preprocessing Optimization, and Planar-SPECT Comparison

Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO

Re: Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer

Re: ctDNA-guided Adjuvant Atezolizumab in Muscle-invasive Bladder Cancer

Real-world use of enfortumab vedotin in metastatic urothelial carcinoma: efficacy, safety, and risk stratification

Treatment Pathway and Clinical Outcomes of the Population with Muscle-invasive Bladder Cancer in Italy: A Real-world Analysis with Administrative Databases

Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study

Adagrasib versus docetaxel in KRAS G12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial.

A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index

Agnostic phase II, multicenter, single-arm study with DURVAlumab plus carboplatin or cisplatin and etoposide as first-line treatment in extensive stage - Extrapulmonary Small Cell Carcinoma (EPSCC) patients – DURVASCC trial (GOIRC-01-2021)

Antibody–drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives

Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy

Collaborators (15)

Fabian Finkelmeier

David J. Pinato

Hong Jae Chon

Salvatore Corallo

Oscar Juan-Vidal

Barletta Giulia

ilhwan kim

Jin Won Kim

Michele Ghidini

Claudiu T Supuran

Giovanni Farinea

Andrea Casadei-Gardini

Lorenza Rimassa

Vanesa GREGORC

Jun Zhang

Make your next move.